LENZ Therapeutics Inc (NASDAQ: LENZ) on Tuesday, soared 14.06% from the previous trading day, before settling in for the closing price of $23.19. Within the past 52 weeks, LENZ’s price has moved between $16.53 and $50.40.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -181.63%. The company achieved an average annual earnings per share of -10.77%. With a float of $26.77 million, this company’s outstanding shares have now reached $28.59 million.
LENZ Therapeutics Inc (LENZ) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of LENZ Therapeutics Inc is 14.45%, while institutional ownership is 86.22%. The most recent insider transaction that took place on Nov 07 ’25, was worth 239,278. In this transaction Director of this company bought 10,500 shares at a rate of $22.79, taking the stock ownership to the 10,500 shares. Before that another transaction happened on Nov 07 ’25, when Company’s Chief Financial Officer bought 2,198 for $22.76, making the entire transaction worth $50,017. This insider now owns 5,386 shares in total.
LENZ Therapeutics Inc (LENZ) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.46 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.4) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.78 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 34.76% during the next five years compared to -181.63% drop over the previous five years of trading.
LENZ Therapeutics Inc (NASDAQ: LENZ) Trading Performance Indicators
LENZ Therapeutics Inc (LENZ) is currently performing well based on its current performance indicators. A quick ratio of 12.63 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 47.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit -0.95 in the next quarter and is forecasted to reach -2.76 in one year’s time.
Technical Analysis of LENZ Therapeutics Inc (LENZ)
The latest stats from [LENZ Therapeutics Inc, LENZ] show that its last 5-days average volume of 2.11 million was superior to 0.46 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 27.74%.
During the past 100 days, LENZ Therapeutics Inc’s (LENZ) raw stochastic average was set at 17.95%, which indicates a significant decrease from 44.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.17 in the past 14 days, which was lower than the 2.37 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.82, while its 200-day Moving Average is $30.92. Now, the first resistance to watch is $27.63. This is followed by the second major resistance level at $28.81. The third major resistance level sits at $30.95. If the price goes on to break the first support level at $24.31, it is likely to go to the next support level at $22.17. The third support level lies at $20.99 if the price breaches the second support level.
LENZ Therapeutics Inc (NASDAQ: LENZ) Key Stats
Market capitalization of the company is 827.61 million based on 31,290K outstanding shares. Right now, sales total 0 K and income totals -49,770 K. The company made 12,500 K in profit during its latest quarter, and -16,700 K in sales during its previous quarter.
